Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LP-300 · 1 trial · 2 indications
Number of days or months from the date of randomization to the earliest of the documented disease progression based on the Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 criteria
Number of days or months between the randomization date and the date of death from all causes
| Arm | Type | Description |
|---|---|---|
| LP-300 in Combination with Pemetrexed and Carboplatin | EXPERIMENTAL | LP-300 (investigational drug) + Pemetrexed and Carboplatin (standard of care chemotherapies) Dosing occurs on Day 1 of a 21-day cycle. |
| Pemetrexed and Carboplatin (Standard of Care) | ACTIVE_COMPARATOR | Pemetrexed and Carboplatin Only (standard of care chemotherapies) Dosing occurs on Day 1 of a 21-day cycle. |
| Name | Type | Description |
|---|---|---|
| LP-300 | DRUG | LP-300: 18.4 g/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion. |
| Pemetrexed | DRUG | Pemetrexed: 500 mg/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. After completion of the 4 to 6 cycles, patients will have the option to continue pemetrexed maintenance therapy until disease progression, unacceptable toxicity, or patient preference/physician discretion. The number of treatment cycles will be determined by PI discretion. |
| Carboplatin | DRUG | Carboplatin: area under the concentration-time curve 5 mg/mL per minute (AUC5) by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion. |
Inclusion Criteria: 1. Patients with confirmed histopathological diagnosis of inoperable advanced (Stage III or IV) primary adenocarcinoma (including bronchioalveolar cell carcinoma) of the lung with specific actionable genomic alterations (e.g., mesenchymal epithelial transition (MET) exon14 skipp...
LP-300 is an investigational small molecule being studied for the treatment of adenocarcinoma of the lung, a type of non-small-cell lung cancer. It is currently in Phase 2 clinical development for this indication.
LP-300 is being developed by Lantern Pharma Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol LTRN. The company is conducting clinical trials of LP-300 in patients with advanced lung adenocarcinoma.
LP-300 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 trial is currently recruiting participants to evaluate its safety and efficacy.
LP-300 is being studied in a Phase 2 clinical trial with the identifier NCT05456256. The trial is titled 'A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma' and is currently recruiting participants in the United States, Japan, and Taiwan.
In the ongoing Phase 2 clinical trial, LP-300 is being studied in combination with carboplatin and pemetrexed. The trial is active-controlled, meaning patients receive either the LP-300 combination or an active comparator, and it is not blinded.